Patients with lung cancer who continue using Avastin [bevacizumab] beyond the median treatment duration will receive the drug free of charge

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.517, 2006-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer

By  

Current Pharmaceutical Design, Vol. 21, Iss. 32, 2015-10 ,pp. : 4763-4772

Bentham Science Publishers

Access to resources Recommend Favorite

Roche's bevacizumab [Avastin] has been approved as a first-line treatment for advanced renal cell cancer in the EU

By  

Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. : 27-27

Adis International

Access to resources Recommend Favorite

Bevacizumab [Avastin; Roche] has been launched in the UK as a first-line treatment for metastatic breast cancer

By  

Inpharma, Vol. 1, Iss. 1589, 2007-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

How can patients who are not referred for treatment receive the best treatment available?

By Warren Graham W.   Marshall James R.   Cummings K. Michael   Singh Anurag K.   Reid Mary E.  

Cancer, Vol. 120, Iss. 11, 2014-06 ,pp. : 1750-1751

Blackwell Publishing

Access to resources Recommend Favorite

Treatment of Lung Cancer Using Nanoparticle Drug Delivery Systems

By  

Current Drug Discovery Technologies, Vol. 10, Iss. 2, 2013-06 ,pp. : 170-176

Bentham Science Publishers

Access to resources Recommend Favorite